USRE29608E - Benzoxazole derivatives - Google Patents

Benzoxazole derivatives Download PDF

Info

Publication number
USRE29608E
USRE29608E US05/764,664 US76466477A USRE29608E US RE29608 E USRE29608 E US RE29608E US 76466477 A US76466477 A US 76466477A US RE29608 E USRE29608 E US RE29608E
Authority
US
United States
Prior art keywords
benzoxazolyl
acid
propionic acid
solution
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/764,664
Inventor
Delme Evans
David William Dunwell
Terence Alan Hicks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Industries Ltd
Unisys Corp
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2340972A external-priority patent/GB1435721A/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Application granted granted Critical
Publication of USRE29608E publication Critical patent/USRE29608E/en
Assigned to BURROUGHS CORPORATION reassignment BURROUGHS CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). DELAWARE EFFECTIVE MAY 30, 1982. Assignors: BURROUGHS CORPORATION A CORP OF MI (MERGED INTO), BURROUGHS DELAWARE INCORPORATED A DE CORP. (CHANGED TO)
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Definitions

  • This invention relates to certain new benzoxazole derivatives which have been found to possess valuable pharmacological activity or are useful as intermediates for preparing such active compounds and to a process by which such compounds may be prepared.
  • the invention also includes pharmaceutical compositions containing said pharmacologically active compounds and a method of treating animals including humans comprising administering thereto an effective dose of said compounds or compositions.
  • the invention also provides novel intermediates from which the benzoxazole derivatives of the present invention may be prepared.
  • C 1-6 alkyl as used herein means a straight or branched chain alkyl group containing from 1 to 6 carbon atoms such as methyl, ethyl, isopropyl, n-butyl, s-butyl, t-butyl, n-amyl, s-amyl, n-hexyl, 2-ethylbutyl and 4-methylamyl.
  • C 1-6 alkoxy means the aforementioned C 1-6 alkyl groups linking through an oxygen atom, or an --SO 2 --, --NH--, --CO-- or --CONH-- group respectively.
  • C 1-6 haloalkyl as used herein means the aforementioned C 1-6 alkyl groups substituted by one or more halogen atoms such as, for example, chloromethyl, bromomethyl, trifluoromethyl, 2-chloroethyl, pentafluoroethyl, 3-bromopropyl, 2-chlorobutyl, 4-bromobutyl, 2-(2-chloroethyl)-3-chloropropyl and 6-chlorohexyl.
  • halogen atoms such as, for example, chloromethyl, bromomethyl, trifluoromethyl, 2-chloroethyl, pentafluoroethyl, 3-bromopropyl, 2-chlorobutyl, 4-bromobutyl, 2-(2-chloroethyl)-3-chloropropyl and 6-chlorohexyl.
  • heteroaryl as used herein means a heterocyclic aromatic group containing at least one ring atom which is not carbon, preferred examples of which are 5- or 6-membered heterocyclic aromatic rings containing one or two ring atoms selected from oxygen, sulphur and nitrogen.
  • sub-group comprises compounds wherein the group --CR 1 R 2 R 3 is in the 5- or 6-position of the benzoxazole nucleus, R 4 is hydrogen, hydroxy, amino, C 1-4 alkyl, cyclohexyl, furyl, thienyl, pyridyl, pyrazinyl, or a phenyl group optionally substituted in any available position by one or two groups selected from halogen, nitro, amino, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, C 2-4 acyl, C 1-4 alkylsulphonyl, trifluoromethyl, pentafluoroethyl, C 1-4 monohaloalkyl or optionally substituted in two adjacent positions by methylene- or ethylene-dioxy, R 1 and R 2 are independently hydrogen, methyl or ethyl, and R 3 is:
  • R 5 is C 1-4 alkyl, amino-C 1-4 alkyl, C 1-4 alkylamino--C 1-4 alkyl or di-C 1-4 alkylamino-C 1-4 alkyl; or
  • D.iii the C 1-4 alkyl, amino-C 1-4 alkyl, dimethylamino-C 1-4 alkyl and diethylamino-C 1-4 alkyl esters of the acids of D(i) above.
  • the present invention also provides a process for preparing the foregoing compounds of formula I which comprises cyclising a compound of the formula:- ##STR4## wherein Z is the group R 3 or a group convertible to R 3 , and either X is hydrogen or the group R 10 CO-- and Y is H 2 N--or X is hydrogen and Y is the group R 10 CO--NH-- or R.sup.
  • R 10 being the same as R 4 with the exception of hydroxy, amino or C 2-7 acylamino, the cyclisation being carried out, in the case where X is hydrogen and Y is H 2 N--, in the presence of a cyclising agent capable of donating the required group R 4 (other than C 2-7 acylamino), and thereafter, where Z in the resultant compound is not the same as group R 3 , it is converted to group R 3 in conventional manner and, if desired, a resultant compound in which R 4 is amino is acylated to produce a compound of formula I in which R 4 is C 2-7 acylamino.
  • Z is preferably hydrogen or halogen and where Z is one the groups encompassed by R 3 , it is preferably a nitrile group or an esterified carboxy, esterified hydroxymethyl, carboxyamide or salified carboxy group.
  • cyclisation of a compound of formula III in which X is hydrogen and Y is R 10 CO--NH-- or in which X is R 10 CO-- and Y is H 2 N may be carried out under the influence of heat and/or under acidic conditions, for example in the presence of hydrochloric acid or polyphosphoric acid.
  • cyclisation is easily accomplished by treatment with an oxidizing agent such as lead tetra-acetate or nickel peroxide.
  • cyclisation is normally accomplished by mixing the cyclising agent with the compound of formula III, usually in a suitable solvent which may be water or an organic solvent such as pyridine, at room temperature or below followed by the application of heat to complete the reaction.
  • a suitable solvent which may be water or an organic solvent such as pyridine
  • This compound, or the same compound obtained directly from the above cyclisation reaction, may then be reacted with an alkali metal cyanide in a suitable diluent or solvent, usually under the influence of heat, to produce a compound of formula I in which R 3 is CN.
  • the nitrile may be reacted with an appropriate alcohol under acidic conditions to produce a compound of formula I in which R 3 is an esterified carboxy group.
  • the nitrile can be hydrolysed, for example using sulphuric acid, to produce a compound of formula I in which R 3 is a carboxyamide group.
  • Hydrolysis of the nitrile, or the last mentioned carboxyamide, with a strong base or an acid such as concentrated hydrochloric acid results in the formation of a compound of formula I in which R 3 is a carboxy group.
  • a resultant compound of formula I in which R 3 is esterified carboxy may be converted to a hydroxamic acid derivative by reaction with hydroxylamine.
  • a resultant acid of formula I i.e. where R 3 is a carboxy group or an ester thereof may readily be reduced, for example using diborane or a complex metal hydride, to yield the corresponding compound of formula I in which R 3 is hydroxymethyl and the alcohol resulting therefrom may then be esterified in conventional manner, for example by reaction with an appropriate carboxylic acid such as a C 2-4 alkanoic acid.
  • An acid of formula I may be salified by treatment with an appropriate base such as an ammonium, alkylammonium, aralkylammonium, aluminium, alkali metal or alkaline earth metal hydroxide and of course a salt of formula I may readily be converted to the free acid by treatment with an acid such as a hydrochloric or sulphuric acid.
  • An acid of formula I or a salt thereof may be converted to an ester by treatment with an appropriate alcohol or by treatment with a halide of the appropriate ester moiety or a salt of that halide if the ester moiety contains a base nitrogen atom.
  • An ester of formula I may of course by hydrolyzed to the corresponding acid or alcohol of formula I by treatment with a suitable hydrolytic agent such as an inorganic base or acid.
  • a suitable hydrolytic agent such as an inorganic base or acid.
  • An acid of formula I or an ester thereof may also be converted to an amide of formula I by reaction with ammonium or an appropriate primary or secondary amine.
  • a resultant compound of formula I in which R 1 and/or R 2 is hydrogen may be alkylated to produce the corresponding compound of formula I in which R 1 and/or R 2 is C 1-6 alkyl.
  • the alkylation may be carried out by interaction of an alkali metal derivative of the appropriate benzoxazole derivative with an alkyl halide such as, for example, methyl or ethyl iodide.
  • a compound of formula I in which group R 4 is not the desired group may be prepared, the oxazole ring in the resultant compound is then cleaved in such a way as to regenerate a compound of formula III in which X is hydrogen and Y is H 2 N--, for example by cleavage with concentrated hydrochloric acid at a temperature of around 150° C., and the resultant compound of formula III is re-cyclised in the presence of a cyclising agent which will donate the required group R 4 .
  • step (a) is accomplished by diazotisation followed by treatment of the resultant diazonium compound with dilute sulphuric acid.
  • Step (b) is carried out by nitration, for example by addition of nitric acid to a solution of the nitrile in glacial acetic acid.
  • Step (f) is accomplished by conventional acylation using an appropriate acylating agent such as an acyl halide or acid anhydride.
  • R 3 is a nitrile group
  • R 3 is carboxy or a salt, ester, amide or hydroxamic acid derivative thereof, or is hydroxymethyl or an ester thereof
  • these compounds have been shown to have low toxicity and to possess analgesic, antipyretic and/or anti-inflammatory activity as well as possessing in certain cases the ability to inhibit prostaglandin synthesis or release.
  • the foregoing activities have been demonstrated in tests carried out in animals usually at doses of from 0.1 to 250 mg/kg.
  • the dose administered may be, for example, between 0.1 and 25 mg./kg. but, of course, doses outside this range may be used at the discretion of the physician treating the patient.
  • the pharmacologically active compounds of formula I may be administered by the enteral or or parenteral routes and for this purpose they will normally be formulated into pharmaceutical compositions comprising the active ingredient in association with at least one pharmaceutically acceptable carrier therefor.
  • compositions form a part of this invention and will normally consist of the active ingredient mixed with a carrier, or diluted by a carrier, or enclosed or encapsulated by a carrier in the form of a capsule, sachet, cachet or other container.
  • the carrier may be a solid, semi-solid or liquid material which serves as a vehicle, excipient, coating agent, or medium for the active ingredient.
  • Some examples of the carriers which may be used are lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, liquid paraffin, cocoa butter, oil of theobroma, alginates, tragacanth, gelatin, methyl cellulose, polyoxyethylene sorbitan monolaurate, methyl- or propyl- hydroxybenzoate, ethyl cellulose acetate phthalate, low viscosity acetyl cellulose acetate, paraffin wax, mineral wax, vegetable wax, vegetable gum, silicone rubbers such as liquid polydimethylsiloxane rubber, plasticised or unplasticised polyvinyl chloride, plasticised polyethylene terephthalate, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol or cross-linked partially hydrolysed polyvinyl acetate.
  • compositions of the invention are formulated in a dosage unit form containing from 1 to 1,000 mg. (preferably 25 to 500 mg.) of the active ingredient.
  • suitable dosage unit forms are tablets, hard or soft gelatin capsules, microcapsules and suppositories as well as drug dispensing systems comprising the active ingredient contained in a flexible, imperforate polymeric material through which the drug may be released slowly by diffusion.
  • drug dispensing systems comprising the active ingredient contained in a flexible, imperforate polymeric material through which the drug may be released slowly by diffusion.
  • dosage unit form as used herein means a physically discrete unit containing the active ingredient, generally in admixture with and/or enclosed by a pharmaceutical carrier, the quantity of active ingredient being such that one or more units are normally required for a single therapeutic administration.
  • compositions of the present invention may also contain one or more pharmacologically active ingredients, for example, acetylsalicyclic acid and salts thereof, caffeine, codeine phosphate, phenylbutazone, paracetamol, dextropropoxyphene and indomethacin.
  • pharmacologically active ingredients for example, acetylsalicyclic acid and salts thereof, caffeine, codeine phosphate, phenylbutazone, paracetamol, dextropropoxyphene and indomethacin.
  • compositions of the present invention will of course be adapted to the particular route of administration.
  • oral administration tablets, pills, capsules, solutions or suspensions may be used
  • parenteral administration sterile injection solutions or suspensions may be used
  • rectal administration suppositories may be used
  • topical administration creams, lotions or ointments may be used.
  • Any of the foregoing compositions may, of course, be formulated in delayed or sustained release form in a manner well known in the art.
  • Finely ground 2-(4-aminophenyl) propiontrile (73 g., 0.5 mole) was suspended in concentrated hydrochloric acid (125 ml.).
  • the stirred suspension was diazotised at 0° - 5° C by the dropwise addition of a solution of sodium nitrite (36.23 g., 0.525 mole) in water (60 ml) during 1 - 2 hours.
  • the almost clear solution was stirred for a further 20 minutes at 5° - 10° C, then poured into a stirred, boiling solution of concentrated sulphuric acid (250 ml.) in water (2.5 l.). After 6 minutes it was cooled in an ice-bath, then extracted with ether (x4).
  • the combined ether extracts were extracted with 2N-sodium hydroxide solution (x6).
  • the combined alkaline extracts were cooled in ice-bath, acidified with concentrated hydrochloric acid and extracted with ether (x3).
  • the combined ether extracts were washed with saturated sodium chloride solution (x3), dried (Na 2 SO 4 ) and evaporated to leave a dark brown oil (66.7 g.) which on distillation gave 2-(4-hydroxyphenyl) propionitrile (59.58 g.), b.p. 112° - 122° C/0.125 mm., m.p. 41° - 46° C.
  • 2-(3-Nitro-4-hydroxyphenyl) propionitrile (123.8 g., 0.64 mole.) was suspended in absolute ethanol (950 ml.) and added during 20 minutes, with cooling, to a solution of stannous chloride dihydrate (437.8 g., 1.94 mole.) in concentrated hydrochloric acid (591 ml., 7 mole.). The addition was made at such a rate that the temperature of the reaction mixture did not exceed 20° C. Stirring of the mixture was continued for a further 19 hours at room temperature. The resulting solution, together with ice (1.75 kg.) was added during one hour to a cooled solution of sodium hydroxide (650 g.) in water (600 ml.).
  • the temperature of the reaction mixture was maintained at 15° - 20° C during the addition.
  • the mixture was stirred for a further 1 hour, and the pH then adjusted to 6 by the addition of concentrated hydrochloric acid.
  • the resulting suspension was filtered and the filtrate saturated with sodium chloride, then extracted with ether (x6).
  • the combined ether extracts were dried (Na 2 SO 4 ) and evaporated to leave a solid (69.15 g.) which was suspended in chloroform and extracted with 2N-hydrochloride acid (x6).
  • the combined acid extracts were neutralised to pH 7-8 by the addition of sodium bicarbonate.
  • the resulting suspensions was extracted with ether (x4).
  • 2-(3-Nitro-4-hydroxyphenyl) propionitrile (38.4 g., 0.2 mole.) was suspended in absolute ethanol (250 ml.) and hydrogenated at 4 atmospheres pressure and room temperature over 10% palladium on charcoal. Hydrogenation was complete in 3.8 hours. The catalyst was removed by filtration. Evaporation of the filtrate yielded 2-(3-amino-4-hydroxyphenyl) propionitrile (17 g.), m.p. 110° C.
  • Benzoyl chloride (27.09 g., 0.19 mole.) was added, with cooling, during 20 minutes to a stirred solution of 2-(3-amino-4-hydroxyphenyl) propionitrile (28.35 g., 0.175 mole.) in dry pyridine (200 ml.) at 0° - 3° C. After addition was complete, the mixture was heated at 100° C. for 1 hour. It was then evaporated under reduced pressure to yield crude 2-(3-benzamido-4-hydroxyphenyl) propionitrile as an oil.
  • This compound was prepared using the procedure described in Example 1.
  • 2-(2-p-Bromophenyl-5-benzoxazolyl) propionic acid one third hydrochloride (4.3 g., 0.012 mole.) was ground in 1N-sodium hydroxide solution (20 ml.). To the suspension was added an equal volume of chloroform. The suspension was stirred, then filtered. Recrystallisation of the solid from aqueous ethanol yielded 2-(2-p-bromophenyl-5-benzoxazolyl) propionic acid, sodium salt, m.p. ⁇ 316° C.
  • Ethyl 2-(3-formamido-4-hydroxyphenyl) propionate (11.39 g., 0.048 mole.) was heated at 250° C ⁇ 5° C in an oil-bath for 20 minutes. After cooling the coil was dissolved in ethyl acetate. The solution was washed with 2N-sodium hydroxide solution (x4), then with water (x2). The solution was dried (Na 2 SO 4 ) and evaporated to give ethyl 2-(5-benzoxazolyl) propionate as an oil (6.55 g.).
  • Benzoyl chloride (79 ml) was slowly added to a stirred suspension of 6-amino-m-cresol (83 gm) in pyridine (600 ml). The temperature was kept below 5° C. The solution was heated under reflux for 2 hr., then was evaporated to dryness to give an oil. This oil was extracted with aqueous 2N sodium hydroxide solution. The aqueous layer was made acid with cooncentrated hydrochloric acid. The solid, N-(2'-hydroxy-4'-methylbenzanilide), m.p. 170° C, was filtered off. This product was heated until no more water was evolved. The resulting liquid was allowed to cool and the solid produced was powdered and taken up in petroleum ether. The solution was treated with carbon and the filtrate evaporated to dryness to yield 6-methyl-2-phenylbenzoxazole, m.p. 93° C.
  • N-Bromosuccinimide 25.9 gm was added to a cold solution of 6-methyl-2-phenylbenzoxazole (30 gm) in carbon tetrachloride (250 ml).
  • Benzoyl peroxide 500 mg was added and the mixture was heated under reflux for 3 hr. in the presence of u.v. light.
  • the solid residue was filtered off.
  • the filtrate was evaporated down slightly, treated with carbon and allowed to cool.
  • the crystals which were formed were recrystallised from benzene to yield 6-bromomethyl-2-phenylbenzoxazole, m.p. 162° C.
  • This compound was prepared by the method described in Example 7(c) from ethyl 2-(3-acetamido-4-hydroxyphenyl)propionate.
  • This compound was prepared from ethyl 2-(2-methyl-5-benzoxazolyl)-propionate using the method of Example 7(d), m.p. 115° - 117° C.
  • Phosgene was bubbled through a stirred solution of 2-(3-amino-4-hydroxyphenyl)propionic acid (3.14 g.) in water (30 ml.) and concentrated hydrochloric acid (2 ml.) for 2 hours. During this time, a small amount of tar was deposited. The aqueous solution was decanted and kept at room temperature for 3 days. A solid was precipitated which was filtered off and recrystallised from 50% aqueous isopropanol to yield the desired hydroxy compound as crystals, m.p. 174° - 176° C.
  • the term "medicament” is used to indicate the compound 2-(2-p-chlorophenyl-5-benzoxazolyl) propionic acid. That compound may of course be replaced by any other active compound of formula I and the amount of medicament may be increased or decreased depending on the degree of activity of the medicament used.
  • Tablets each containing 100 mg of medicament are made as follows:
  • the medicament, starch and lactose are passed through a No. 44 mesh B.S.S. sieve and mixed thoroughly.
  • the solution of ethyl cellulose is mixed with the resultant powders which are then passed through a No. 12 mesh B.S.S. sieve.
  • the granules produced are dried at 50°-60° C. and then passed through a No. 16 mesh B.S.S. sieve.
  • the alginic acid, magnesium stearate and talc previously passed through a No. 60 mesh B.S.S. sieve, are added to the granules, mixed and compressed in a tabletting machine to yield tablets each weighing 175 mg.
  • Capsules each containing 200 mg of medicament are made as follows:
  • the medicament, lactose and magnesium stearate are passed through a No. 44 mesh B.S.S. sieve and filled into hard gelatine capsules in 250 mg quantities.
  • Injection solutions each containing 100 mg of medicament per 5 ml solution are made as follows:
  • the medicament is suspended in the water and the sodium hydroxide solution added drop by drop with stirring until the medicament is in solution.
  • the pH of the solution is adjusted to between 8.0 and 8.5, the solution is sterilised by filtration through a bacteria-proof filter and filled into previously sterilised glass ampoules which are then hermetically sealed under aseptic conditions.
  • Suppositories each containing 250 mg of medicament are made as follows:
  • the medicament is passed through a No. 60 mesh B.S.S. sieve and suspended in the theobroma oil previously melted using the minimum of heat necessary
  • the mixture is then poured into a suppository mould of nominal 2 g capacity and allowed to cool.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention provides novel 5- and 6-benzoxazolyl alkanoic acids, optionally substituted in the 2-position, and derivatives thereof which possess anti-inflammatory, anti-pyretic and analgesic activity. Also provided is a process for preparing such compounds by cyclizing an appropriately substituted o-aminophenol and, if necessary, converting the resultant benzoxazole to the desired compound.

Description

This invention relates to certain new benzoxazole derivatives which have been found to possess valuable pharmacological activity or are useful as intermediates for preparing such active compounds and to a process by which such compounds may be prepared. The invention also includes pharmaceutical compositions containing said pharmacologically active compounds and a method of treating animals including humans comprising administering thereto an effective dose of said compounds or compositions. The invention also provides novel intermediates from which the benzoxazole derivatives of the present invention may be prepared.
According to the present invention therefore, there are provided novel benzoxazole derivatives of the formula: ##STR1## wherein the group --CR.sup. 1 R.sup. 2 R3 is in the 5- or 6-position of the benzoxazole nucleus, R1 and R2 are independently hydrogen or C1-6 alkyl, R3 is a nitrile group, carboxy or a salt, ester, amide or hydroxamic acid derivative thereof, or hydroxymethyl or an ester thereof, and R4 is hydrogen, hydroxy, amino, C2-7 acylamino, C1-6 alkyl, cyclohexyl, or a heteroaryl or phenyl group optionally substituted in any available position by one or more C1-6 alkylsulphonyl, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, nitro, C2-7 acyl, hydroxy, amino, C1-6 alkylamino, or C2-7 acylamino or optionally substituted in two adjacent positions by methylene- or ethylenedioxy.
The term "C1-6 alkyl" as used herein means a straight or branched chain alkyl group containing from 1 to 6 carbon atoms such as methyl, ethyl, isopropyl, n-butyl, s-butyl, t-butyl, n-amyl, s-amyl, n-hexyl, 2-ethylbutyl and 4-methylamyl. Similarly the terms "C1-6 alkoxy", "C1-6 alkylsulphonyl", "C1-6 alkylamino", "C2-7 acyl", and "C2-7 acylamino" mean the aforementioned C1-6 alkyl groups linking through an oxygen atom, or an --SO2 --, --NH--, --CO-- or --CONH-- group respectively. The term "C1-6 haloalkyl" as used herein means the aforementioned C1-6 alkyl groups substituted by one or more halogen atoms such as, for example, chloromethyl, bromomethyl, trifluoromethyl, 2-chloroethyl, pentafluoroethyl, 3-bromopropyl, 2-chlorobutyl, 4-bromobutyl, 2-(2-chloroethyl)-3-chloropropyl and 6-chlorohexyl. The term "heteroaryl" as used herein means a heterocyclic aromatic group containing at least one ring atom which is not carbon, preferred examples of which are 5- or 6-membered heterocyclic aromatic rings containing one or two ring atoms selected from oxygen, sulphur and nitrogen.
Within the aforementioned group of compounds of formula I, there is a sub-group preferred for the ease of availability of the necessary starting materials, which sub-group comprises compounds wherein the group --CR1 R2 R3 is in the 5- or 6-position of the benzoxazole nucleus, R4 is hydrogen, hydroxy, amino, C1-4 alkyl, cyclohexyl, furyl, thienyl, pyridyl, pyrazinyl, or a phenyl group optionally substituted in any available position by one or two groups selected from halogen, nitro, amino, hydroxy, C1-4 alkyl, C1-4 alkoxy, C2-4 acyl, C1-4 alkylsulphonyl, trifluoromethyl, pentafluoroethyl, C1-4 monohaloalkyl or optionally substituted in two adjacent positions by methylene- or ethylene-dioxy, R1 and R2 are independently hydrogen, methyl or ethyl, and R3 is:
i. the group --COOR5, where R5 is C1-4 alkyl, amino-C1-4 alkyl, C1-4 alkylamino--C1-4 alkyl or di-C1-4 alkylamino-C1-4 alkyl; or
ii. the group --CO--R6 where R6 is --NHOH or --NR7 R8 where R7 and R8 are independently hydrogen or C1-4 alkyl; or
iii. the group --CH2 OR9 where R9 is hydrogen or C1-4 alkyl; or
iv. the group --COOH or an alkali or alkaline earth metal, aluminium or ammonium salt thereof; or
v. a nitrile group.
Using standard test procedures in animals, compounds of the foregoing type have been assessed for pharmacological activity and lack of toxicity. Such tests have revealed a further group of compounds in which the combination of high activity, especially anti-inflammatory activity, and low toxicity is most marked. This especially useful group of compounds fall within the general formula: ##STR2## wherein the group ##STR3## is in the 5- or 6-position of the benzoxazole nucleus, R4 is a phenyl group optionally substituted by one or two groups selected from halogen, trifluoromethyl, methyl, methoxy, acetyl, methylsulphonyl, nitro or hydroxy, R2 is hydrogen or most advantageously methyl, and R3 is as defined in parts (i) to (iv) above, especially parts (i) and (iv).
Examples which may be given of the compounds of this invention are:
5-benzoxazolyl acetic acid
5-benzoxazolyl acetonitrile
2-(5-benzoxazolyl) propionic acid
2-(5-benzoxazolyl) propionitrile
2-(5-benzoxazolyl) butyric acid
2-methyl-2-(5-benzoxazolyl) propionic acid
2-(6-benzoxazolyl) propionic acid
2-(6-benzoxazolyl) propionitrile
2-(6-benzoxazolyl) butyric acid
2-(6-benzoxazolyl) isobutyric acid
sodium 2-(6-benzoxazolyl) propionate
ethyl 6-benzoxazolyl acetate
diethylaminomethyl 2-(5-benzoxazolyl) propionate
5-benzoxazolyl acetamide
N,n-dimethyl 6-benzoxazolylpropionamide
2-(5-benzoxazolyl) propionylhydroxamic acid
2-hydroxy-5-benzoxazolyl acetic acid
2-(2-hydroxy-6-benzoxazolyl) propionic acid
2-(2-methyl-6-benzoxazolyl) butyric acid
ethyl 2-(2-t-butyl-5-benzoxazolyl) propionate
2-(2-isopropyl-5-benzoxazolyl) propionamide
2-(5-benzoxazolyl) propyl alcohol
2-(2-n-butyl-6-benzoxazolyl) propionic acid
2-cyclohexyl-5-benzoxazolyl acetic acid
2-cyclohexyl-5-benzoxazolyl acetonitrile
2-cyclohexyl-6-benzoxazolyl acetic acid
methyl 2-(2-cyclohexyl-5-benzoxazolyl) propionate
dimethylaminoethyl 2-cyclohexyl-5-benzoxazolyl acetate
potassium 2-(2-cyclohexyl-5-benzoxazolyl) butyric acid
2-(2-amino-6-benzoxazolyl) propyl alcohol
2-(2-amino-5-benzoxazolyl) propionic acid
2-amino-5-benzoxazolyl acethydroxamic acid
2-[2-(fur-2-yl)-5-benzoxazolyl]-2-methylpropionic acid
2-[2-(fur-2-yl)-6-benzoxazolyl] propionic acid
t-butyl 2-(fur-2-yl)-5-benzoxazolyl acetate
2-[2-(fur-3-yl)-5-benzoxazolyl] ethanol
2-[2-(fur-2-yl)-5-benzoxazolyl] propionitrile
2-[2-(thien-2-yl)-5-benzoxazolyl] propyl alcohol
2-[2-(thien-2-yl)-6-benzoxazolyl]-2-ethyl propionic acid
ethyl 2-(thien-3-yl)-5-benzoxazolyl acetate
2-(thien-3-yl)-5-benzoxazolyl acethydroxamic acid
2-(pyrid-4-yl)-5-benzoxazolyl acetic acid
2-(pyrid-2-yl)-6-benzoxazolyl acetonitrile
2-[2-(pyrid-2-yl)-5-benzoxazolyl]propionic acid
isopropyl 2-[2 -(pyrid-2-yl)-6-benzoxazolyl] propionate
2-[2-(pyrid-2-yl)-6-benzoxazolyl) propyl alcohol
2-(pyrazin-2-yl)-6-benzoxazolyl acetic acid
2-(pyrazin-2-yl)-6-benzoxazolyl ethyl alcohol
2-[2-(pyrazin-2-yl)-5-benzoxazolyl] propionic acid
ethyl 2-[2-(pyrazin-2-yl)-5-benzoxazolyl] propionate
2-[2-(4-chlorophenyl)-5-and 6-benzoxazolyl] propionitrile
2-(4-nitrophenyl)-5-benzoxazolyl acetic acid
2-(4-aminophenyl)-6-benzoxazolyl acetic acid
ethyl 2-[2-(3,4-methylenedioxyphenyl)-5-benzoxazolyl] propionate
2-[2-(4-β-chloroethylphenyl)-6-benzoxazolyl] propionic acid
2-[2-(3,4-diethylphenyl)-5-benzoxazolyl] propionic acid
2-(3-ethoxyphenyl)-5-benzoxazolyl acethydroxamic acid
2-(4-hydroxyphenyl)-6-benzoxazolyl ethanol
ethyl 2-(4-dimethylaminophenyl)-5-benzoxazolyl acetate
2-(3,4-dihydroxyphenyl)-5-benzoxazolyl acetic acid
2-[2-(4-t-butoxyphenyl)-6-benzoxazolyl] butyric acid
2-[2-(4-chlorophenyl)-5-benzoxazolyl] butyronitrile
diethylaminoethyl 2-(2-methoxyphenyl)-5-benzoxazolyl acetate
2-[2-(2,4-dinitrophenyl)-5-benzoxazolyl] propyl alcohol
2-[2-(4-aminophenyl)-6-benzoxazolyl] propionylhydroxamic acid
sodium 2-(4-n-butylphenyl)-5-benzoxazolyl acetate
Examples of preferred compounds of the present invention are:
A. i. 2-phenyl-5- and 6-benzoxazolyl acetic acid
2-(4-chlorophenyl)-5- and 6-benzoxazolyl acetic acid
2-(4-methylphenyl)-5- and 6-benzoxazolyl acetic acid
2-(4-trifluoromethylphenyl)-5- and 6-benzoxazolyl acetic acid
2-(4-methoxyphenyl)-5- and 6-benzoxazolyl acetic acid
2-(4-bromophenyl)-5- and 6-benzoxazolyl acetic acid
2-(4-fluorophenyl)-5- and 6-benzoxazolyl acetic acid
2-(3-chlorophenyl)-5- and 6-benzoxazolyl acetic acid
2-(3-methylphenyl)-5- and 6-benzoxazolyl acetic acid
2-(3-trifluoromethylphenyl)-5- and 6-benzoxazolyl acetic acid
2-(3,4-dichlorophenyl)-5- and 6-benzoxazolyl acetic acid
2-(2-methylphenyl)-5- and 6-benzoxazolyl acetic acid
2-(2-chlorophenyl)-5- and 6-benzoxazolyl acetic acid
2-(2-methoxyphenyl)-5- and 6-benzoxazolyl acetic acid
2-(3,4-dimethylphenyl)-5- and 6-benzoxazolyl acetic acid
A. ii. the sodium, potassium, aluminium and ammonium salts of the acids of A(i) above,
A. iii. the C1-4 alkyl, amino-C1-4 alkyl, dimethylamino-C1-4 alkyl and diethylamino-C1-4 alkyl esters of the acids of A(i) above,
B. 2-phenyl-5- and 6-benzoxazolyl acetamide
2-phenyl-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-chlorophenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-chlorophenyl)-5- and 6-benzoxazolyl acetamide
2-(4-bromophenyl)-5- and 6-benzoxazolyl acetamide
2-(4-fluorophenyl)-5- and 6-benzoxazolyl acetamide
2-(4-methylphenyl)-5- and 6-benzoxazolyl acetamide
2-(4-methoxyphenyl)-5- and 6-benzoxazolyl acetamide
2-(2-methoxyphenyl)-5- and 6-benzoxazolyl acetamide
2-(2-chlorophenyl)-5- and 6-benzoxazolyl acetamide
2-(3,4-dichlorophenyl)-5- and 6-benzoxazolyl acetamide
2-(3-chlorophenyl)-5- and 6-benzoxazolyl acetamide
2-(3-methylphenyl)-5- and 6-benzoxazolyl acetamide
2-(4-trifluoromethylphenyl)-5- and 6-benzoxazolyl acetamide
2-(4-trifluoromethylphenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-bromophenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-fluorophenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(3,4-dimethylphenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-methoxyphenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(4-methylphenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-(3-chlorophenyl)-5- and 6-benzoxazolyl acethydroxamic acid
2-[2-(3-chlorophenyl)-5- and 6-benzoxazolyl]propionylhydroxamic acid
2-[2-(4-chlorophenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(2-chlorophenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(3,4-dichlorophenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(4-trifluoromethylphenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(4-methylphenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(4-methoxyphenyl)-5-and 6-benzoxazolyl] propionylhydroxamic acid
2-[2-(3-methoxyphenyl)-5-and 6-benzoxazolyl] propionamide
2-[2-(4-methylphenyl-5-and 6-benzoxazolyl] propionamide
2-[2-(4-trifluoromethylphenyl)-5-and 6-benzoxazolyl] propionamide
2-[2-(4-methoxyphenyl)-5-and 6-benzoxazolyl] propionamide
2-[2-(4-chlorophenyl)-5-and 6-benzoxazolyl] propionamide
2-[2-(4-bromophenyl)-5- and 6-benzoxazolyl] propionamide
2-[2-(4-fluorophenyl)-5-and 6-benzoxazolyl] propionamide
C.i. 2-phenyl-5- and 6-benzoxazolyl ethanol
2-(4-chlorophenyl)-5-and 6-benzoxazolyl ethanol
2-(4-methylphenyl)-5-and 6-benzoxazolyl ethanol
2-(4-trifluoromethylphenyl)-5- and 6-benzoxazolyl ethanol
2-(4-methoxyphenyl)-5-and 6-benzoxazolyl ethanol
2-(4-bromophenyl)-5-and 6-benzoxazolyl ethanol
2-(4-fluorophenyl)-5-and 6-benzoxazolyl ethanol
2-(3-chlorophenyl)-5-and 6-benzoxazolyl ethanol
2-(3-methylphenyl)-5-and 6-benzoxazolyl ethanol
2-(3,4-dichlorophenyl)-5-and 6-benzoxazolyl ethanol
2-(methylphenyl)-5-and 6-benzoxazolyl ethanol
2-(2-methoxyphenyl)-5-and 6-benzoxazolyl ethanol
2-(2-chlorophenyl)-5-and 6-benzoxazolyl ethanol
2-[2-(2-chlorophenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(3-chlorophenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(4-chlorophenyl)-5-and 6 -benzoxazolyl] propyl alcohol
2-[2-(3,4-dichlorophenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(3,4-dimethylphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(3-methylphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(4-methylphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(4-trifluoromethylphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(4-methoxyphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(4-bromophenyl)-5- and 6-benzoxazolyl] propyl alcohol
2-[2-(4-fluorophenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(2-methylphenyl)-5-and 6-benzoxazolyl] propyl alcohol
2-[2-(2-methoxyphenyl)-5-and 6-benzoxazolyl] propyl alcohol
C.ii. the C1-4 alkyl esters of the alcohols of C(i) above,
Examples of the most preferred compounds of the invention are:
Di. 2-[2-phenyl-5- and 6-benzoxazolyl] propionic acid
2-[2-(3,4-dimethoxyphenyl)-5-and 6-benzoxazolyl] propionic acid
2-[2-(3,4-methylenedioxyphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-chlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-fluorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-methylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3,4-dichlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3,5-dichlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2,4-dichlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3-chlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3-trifluoromethylphenyl-5- and 6-benzoxazolyl] propionic acid
2-[2-(3-fluorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3-methylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-iodophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-chlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-hydroxy-4-chlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-bromophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-nitrophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-fluorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(3-nitro-4-chlorophenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-methylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-acetylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-trifluoromethylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-methoxyphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(4-methylsulphonylphenyl)-5- and 6-benzoxazolyl] propionic acid
2-[2-(2-methoxyphenyl)-5- and 6-benzoxazolyl] propionic acid
D. ii. the sodium, potassium, aluminium and ammonium salts of the acids of D(i) above, and
D.iii. the C1-4 alkyl, amino-C1-4 alkyl, dimethylamino-C1-4 alkyl and diethylamino-C1-4 alkyl esters of the acids of D(i) above.
The present invention also provides a process for preparing the foregoing compounds of formula I which comprises cyclising a compound of the formula:- ##STR4## wherein Z is the group R3 or a group convertible to R3, and either X is hydrogen or the group R10 CO-- and Y is H2 N--or X is hydrogen and Y is the group R10 CO--NH-- or R.sup. 10 CH=N--, R10 being the same as R4 with the exception of hydroxy, amino or C2-7 acylamino, the cyclisation being carried out, in the case where X is hydrogen and Y is H2 N--, in the presence of a cyclising agent capable of donating the required group R4 (other than C2-7 acylamino), and thereafter, where Z in the resultant compound is not the same as group R3, it is converted to group R3 in conventional manner and, if desired, a resultant compound in which R4 is amino is acylated to produce a compound of formula I in which R4 is C2-7 acylamino.
In carrying out the foregoing cyclisation using a compound of formula III in which X is hydrogen and Y is H2 N--, it will be appreciated that, if group Z is also capable of reacting with the cyclising agent used, the reaction may produce a mixture of products rather than the desired compound of formula I alone. Although the undesired products could be separated from the reaction mixture, it is obviously desirable to use a compound of formula III in which Z is a group which is incapable of reaction with the cyclising agent. Thus, in the case where Z is a group convertible to R3, Z is preferably hydrogen or halogen and where Z is one the groups encompassed by R3, it is preferably a nitrile group or an esterified carboxy, esterified hydroxymethyl, carboxyamide or salified carboxy group.
The cyclisation of a compound of formula III in which X is hydrogen and Y is R10 CO--NH-- or in which X is R10 CO-- and Y is H2 N may be carried out under the influence of heat and/or under acidic conditions, for example in the presence of hydrochloric acid or polyphosphoric acid. In the case where X is hydrogen and Y is R10 CH=N--, cyclisation is easily accomplished by treatment with an oxidizing agent such as lead tetra-acetate or nickel peroxide.
When a compound of formula III in which X is hydrogen and Y is H2 N-- is used, cyclisation is normally accomplished by mixing the cyclising agent with the compound of formula III, usually in a suitable solvent which may be water or an organic solvent such as pyridine, at room temperature or below followed by the application of heat to complete the reaction. Examples of suitable cyclising agents which may be used are compounds of the formulae R10 COOH, (R10 CO)2 O, R10 COCl, R10 CONH2, R10 CONHNH2, R10 CN, R10 C(OR')=NH and R10 CCl=NR' where R' is C1-4 alkyl, or the cyclising agent may be a cyanogen halide, preferably cyanogen bromide, when R4 =NH2 is required, or phosgene when R4 =OH is required.
As stated above, when Z is not the group R3, completion of the cyclisation step must be followed by conversion of group Z to the desired group R3. As is well known in the art, many different types of groups may be converted to the R3 functions in the desired compounds of this invention. However, it is preferred for the purposes of the present invention that, where Z is not the group R3, it is hydrogen or halogen. When Z is hydrogen, the compound resulting from the cyclisation reaction may be halogenated in conventional manner, for example using chlorine, sulphurylchloride, bromine or N-bromosuccinimide, preferably in the presence of a suitable solvent such as carbon tetrachloride to produce the corresponding compound in which Z is halogen. This compound, or the same compound obtained directly from the above cyclisation reaction, may then be reacted with an alkali metal cyanide in a suitable diluent or solvent, usually under the influence of heat, to produce a compound of formula I in which R3 is CN.
The latter compound, or the same compound obtained directly from the above cyclisation reaction, may then be treated in a number of ways to achieve its conversion to another compound of formula I. For example, the nitrile may be reacted with an appropriate alcohol under acidic conditions to produce a compound of formula I in which R3 is an esterified carboxy group. Alternatively, the nitrile can be hydrolysed, for example using sulphuric acid, to produce a compound of formula I in which R3 is a carboxyamide group. Hydrolysis of the nitrile, or the last mentioned carboxyamide, with a strong base or an acid such as concentrated hydrochloric acid results in the formation of a compound of formula I in which R3 is a carboxy group. A resultant compound of formula I in which R3 is esterified carboxy may be converted to a hydroxamic acid derivative by reaction with hydroxylamine. A resultant acid of formula I, i.e. where R3 is a carboxy group or an ester thereof may readily be reduced, for example using diborane or a complex metal hydride, to yield the corresponding compound of formula I in which R3 is hydroxymethyl and the alcohol resulting therefrom may then be esterified in conventional manner, for example by reaction with an appropriate carboxylic acid such as a C2-4 alkanoic acid.
An acid of formula I may be salified by treatment with an appropriate base such as an ammonium, alkylammonium, aralkylammonium, aluminium, alkali metal or alkaline earth metal hydroxide and of course a salt of formula I may readily be converted to the free acid by treatment with an acid such as a hydrochloric or sulphuric acid. An acid of formula I or a salt thereof may be converted to an ester by treatment with an appropriate alcohol or by treatment with a halide of the appropriate ester moiety or a salt of that halide if the ester moiety contains a base nitrogen atom. An ester of formula I may of course by hydrolyzed to the corresponding acid or alcohol of formula I by treatment with a suitable hydrolytic agent such as an inorganic base or acid. An acid of formula I or an ester thereof may also be converted to an amide of formula I by reaction with ammonium or an appropriate primary or secondary amine.
A resultant compound of formula I in which R1 and/or R2 is hydrogen may be alkylated to produce the corresponding compound of formula I in which R1 and/or R2 is C1-6 alkyl. The alkylation may be carried out by interaction of an alkali metal derivative of the appropriate benzoxazole derivative with an alkyl halide such as, for example, methyl or ethyl iodide.
Finally, in a situation where it may prove difficult by the above route to produce a compound of formula I in which both the group R4 and the group --CR1 R2 R3 have the desired meanings, a compound of formula I in which group R4 is not the desired group may be prepared, the oxazole ring in the resultant compound is then cleaved in such a way as to regenerate a compound of formula III in which X is hydrogen and Y is H2 N--, for example by cleavage with concentrated hydrochloric acid at a temperature of around 150° C., and the resultant compound of formula III is re-cyclised in the presence of a cyclising agent which will donate the required group R4.
The compounds of formula III above in which Z is the group R3 and X and Y are as defined above are novel compounds. Such novel compounds form a part of this invention and may be prepared by reducing the corresponding nitro compounds in the case where a compound of formula III in which Y = H2 N-- is required, followed by acylation of a resulting compound in which X is hydrogen and Y is H2 N-- or treatment of the latter compound with the aldehyde R10 CHO to produce a compound of formula III in which Y is the group R10 CO--NH-- or R10 CH=N-- respectively.
The following reaction scheme shows the preparation of the above mentioned nitro intermediates from known or readily prepared chemicals. ##STR5##
In the above scheme, step (a) is accomplished by diazotisation followed by treatment of the resultant diazonium compound with dilute sulphuric acid. Step (b) is carried out by nitration, for example by addition of nitric acid to a solution of the nitrile in glacial acetic acid. Steps (c), (d) and (e) are as described above in connection with the conversion of Z=H → Z=Halogen → Z=CN → Z=R3. Step (f) is accomplished by conventional acylation using an appropriate acylating agent such as an acyl halide or acid anhydride.
The compounds of formula I above in which R3 is a nitrile group are, as can be seen from the foregoing description, useful as intermediates for conversion to other compounds of formula I. These other compounds, i.e. where R3 is carboxy or a salt, ester, amide or hydroxamic acid derivative thereof, or is hydroxymethyl or an ester thereof, are useful in that they are pharmacologically active. In particular, these compounds have been shown to have low toxicity and to possess analgesic, antipyretic and/or anti-inflammatory activity as well as possessing in certain cases the ability to inhibit prostaglandin synthesis or release.
The foregoing activities have been demonstrated in tests carried out in animals usually at doses of from 0.1 to 250 mg/kg. In the treatment of humans, the dose administered may be, for example, between 0.1 and 25 mg./kg. but, of course, doses outside this range may be used at the discretion of the physician treating the patient. The pharmacologically active compounds of formula I may be administered by the enteral or or parenteral routes and for this purpose they will normally be formulated into pharmaceutical compositions comprising the active ingredient in association with at least one pharmaceutically acceptable carrier therefor. Such compositions form a part of this invention and will normally consist of the active ingredient mixed with a carrier, or diluted by a carrier, or enclosed or encapsulated by a carrier in the form of a capsule, sachet, cachet or other container. The carrier may be a solid, semi-solid or liquid material which serves as a vehicle, excipient, coating agent, or medium for the active ingredient. Some examples of the carriers which may be used are lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, liquid paraffin, cocoa butter, oil of theobroma, alginates, tragacanth, gelatin, methyl cellulose, polyoxyethylene sorbitan monolaurate, methyl- or propyl- hydroxybenzoate, ethyl cellulose acetate phthalate, low viscosity acetyl cellulose acetate, paraffin wax, mineral wax, vegetable wax, vegetable gum, silicone rubbers such as liquid polydimethylsiloxane rubber, plasticised or unplasticised polyvinyl chloride, plasticised polyethylene terephthalate, modified collagen, cross-linked hydrophilic polyether gel, cross-linked polyvinyl alcohol or cross-linked partially hydrolysed polyvinyl acetate.
Advantageously the compositions of the invention are formulated in a dosage unit form containing from 1 to 1,000 mg. (preferably 25 to 500 mg.) of the active ingredient. Examples of suitable dosage unit forms are tablets, hard or soft gelatin capsules, microcapsules and suppositories as well as drug dispensing systems comprising the active ingredient contained in a flexible, imperforate polymeric material through which the drug may be released slowly by diffusion. More generally, the term "dosage unit form" as used herein means a physically discrete unit containing the active ingredient, generally in admixture with and/or enclosed by a pharmaceutical carrier, the quantity of active ingredient being such that one or more units are normally required for a single therapeutic administration.
In addition to the active ingredient of formula I, the compositions of the present invention may also contain one or more pharmacologically active ingredients, for example, acetylsalicyclic acid and salts thereof, caffeine, codeine phosphate, phenylbutazone, paracetamol, dextropropoxyphene and indomethacin.
The compositions of the present invention will of course be adapted to the particular route of administration. Thus, for oral administration, tablets, pills, capsules, solutions or suspensions may be used, for parenteral administration, sterile injection solutions or suspensions may be used; for rectal administration, suppositories may be used; and for topical administration, creams, lotions or ointments may be used. Any of the foregoing compositions may, of course, be formulated in delayed or sustained release form in a manner well known in the art.
The following examples will further illustrate the preparation of the novel intermediates and novel end-products of formula I:
EXAMPLE 1 2-(2-Phenyl-5-benzoxazolyl) propionic acid
a. 2-(4-Hydroxyphenyl) propiontrile
Finely ground 2-(4-aminophenyl) propiontrile (73 g., 0.5 mole) was suspended in concentrated hydrochloric acid (125 ml.). The stirred suspension was diazotised at 0° - 5° C by the dropwise addition of a solution of sodium nitrite (36.23 g., 0.525 mole) in water (60 ml) during 1 - 2 hours. The almost clear solution was stirred for a further 20 minutes at 5° - 10° C, then poured into a stirred, boiling solution of concentrated sulphuric acid (250 ml.) in water (2.5 l.). After 6 minutes it was cooled in an ice-bath, then extracted with ether (x4). The combined ether extracts were extracted with 2N-sodium hydroxide solution (x6). The combined alkaline extracts were cooled in ice-bath, acidified with concentrated hydrochloric acid and extracted with ether (x3). The combined ether extracts were washed with saturated sodium chloride solution (x3), dried (Na2 SO4) and evaporated to leave a dark brown oil (66.7 g.) which on distillation gave 2-(4-hydroxyphenyl) propionitrile (59.58 g.), b.p. 112° - 122° C/0.125 mm., m.p. 41° - 46° C.
Analysis : Calculated C : 73.44, H : 6.16, N : 9.51 Found C : 73.19, H : 5.91, N : 9.31.
b. 2-(3-Nitro-4-hydroxyphenyl) propionitrile
A solution of 2-(4-hydroxyphenyl) propionitrile (7.79 g., 0.053 mole.) in glacial acetic acid (10 ml.) was added at 7° - 10° C, with stirring, to 12 N-nitric acid (8 ml.) during 45 minutes. A further volume (10 ml.) of glacial acetic acid was added during this period. The resulting yellow suspension was stirred for a further 30 minutes at 7° - 10° C, then for 30 minutes at -10° C to -15° C. The suspension was diluted with water (approx. 90 ml.). Filtration yielded 2-(3-nitro-4-hydroxyphenyl) propionitrile as a yellow solid (8.43 g.), m.p. 78° - 81° C.
Analysis : Calculated C : 56.24, H : 4.19, N : 14.57 Found C : 56.29, H : 4.24, N : 14.47
c. i. 2-(3-Amino-4-hydroxyphenyl) propionitrile
2-(3-Nitro-4-hydroxyphenyl) propionitrile (123.8 g., 0.64 mole.) was suspended in absolute ethanol (950 ml.) and added during 20 minutes, with cooling, to a solution of stannous chloride dihydrate (437.8 g., 1.94 mole.) in concentrated hydrochloric acid (591 ml., 7 mole.). The addition was made at such a rate that the temperature of the reaction mixture did not exceed 20° C. Stirring of the mixture was continued for a further 19 hours at room temperature. The resulting solution, together with ice (1.75 kg.) was added during one hour to a cooled solution of sodium hydroxide (650 g.) in water (600 ml.). The temperature of the reaction mixture was maintained at 15° - 20° C during the addition. The mixture was stirred for a further 1 hour, and the pH then adjusted to 6 by the addition of concentrated hydrochloric acid. The resulting suspension was filtered and the filtrate saturated with sodium chloride, then extracted with ether (x6). The combined ether extracts were dried (Na2 SO4) and evaporated to leave a solid (69.15 g.) which was suspended in chloroform and extracted with 2N-hydrochloride acid (x6). The combined acid extracts were neutralised to pH 7-8 by the addition of sodium bicarbonate. The resulting suspensions was extracted with ether (x4). The combined ether extracts were washed twice with water, dried (Na2 SO4), and evaporated to yield 2-(3-amino-4-hydroxyphenyl) propionitrile as a light brown solid (62.85 g.), m.p. 110° - 112° C.
Analysis : Calculated C : 66.64, H : 6.21, N : 17.27 Found C : 66.45, H : 6.09, N : 16.99
c. ii. 2-(3-Amino-4-hydroxyphenyl) propionitrile was also prepared by the following method:
2-(3-Nitro-4-hydroxyphenyl) propionitrile (38.4 g., 0.2 mole.) was suspended in absolute ethanol (250 ml.) and hydrogenated at 4 atmospheres pressure and room temperature over 10% palladium on charcoal. Hydrogenation was complete in 3.8 hours. The catalyst was removed by filtration. Evaporation of the filtrate yielded 2-(3-amino-4-hydroxyphenyl) propionitrile (17 g.), m.p. 110° C.
d. 2-(3-Benzamido-4-hydroxyphenyl) propionitrile
Benzoyl chloride (27.09 g., 0.19 mole.) was added, with cooling, during 20 minutes to a stirred solution of 2-(3-amino-4-hydroxyphenyl) propionitrile (28.35 g., 0.175 mole.) in dry pyridine (200 ml.) at 0° - 3° C. After addition was complete, the mixture was heated at 100° C. for 1 hour. It was then evaporated under reduced pressure to yield crude 2-(3-benzamido-4-hydroxyphenyl) propionitrile as an oil.
e. 2-(2-Phenyl-5-benzoxazolyl) propionitrile
The oil from (d) above was boiled for 30 minutes during which time the temperature of the vapour above the oil rose to 130° C. On cooling the residue solidified. Recrystallisation of the solid from methanol yielded 2-(2-phenyl-5-benzoxazolyl) propionitrile (27.65 g.), m.p. 118° - 120° C.
Analysis : Calculated C : 77.39, H : 4.87, N : 11.28 Found C : 77.23, H : 5.11, N : 11.34
f. 2-(2-Phenyl-5-benzoxazolyl) propionic acid
A solution of 2-(2-phenyl-5-benzoxazolyl) propionitrile (24 g., 0.096 mole.) in concentrated hydrochloric acid (220 ml.) was refluxed for 2.5 hours. The mixture was poured into ice/water (1 liter). The precipitated 2-(2-phenyl-5-benzoxazolyl) propionic acid was filtered off and washed well with water. The dry acid weighed 23 g. and had m.p. 177° - 179° C.
Analysis : Calculated C : 71.89, H : 4.90, N : 5.24 Found C : 72.13, H : 4.95; N : 5.39
EXAMPLE 2
In a similar manner to that of Example 1, the following compounds were synthesised:
a. 2-(2-p-Fluorophenyl-5-benzoxazolyl) propionic acid, m.p. 162° - 64° C.
Analysis : Calculated C : 67.36, H : 4.24, N : 491 Found C : 67.58, H : 4.45, N : 5.07
b. 2-(2-p-Chlorophenyl-5-benzoxazolyl) propionic acid, m.p. 188° - 191° C.
Analysis : Calculated C : 63.68, H : 4.00, N : 4.64 Found C : 63.50, H : 4.16, N : 4.72
c. 2-(2-m-Chlorophenyl-5-benzoxazolyl) propionic acid, m.p. 173° - 175° C
Analysis : Calculated C : 63.68, H : 4.00, N : 4.64 Found C : 63.50, H : 4.01, N : 4.75
d. 2(2-p-Methylphenyl-5-benzoxazolyl) propionic acid, m.p. 166° - 168° C.
Analysis : Calculated C : 72.58, H : 5.37, N : 4.97 Found C : 72.36, H : 5.46, N : 5.4
e. 2-(2-m-Methylphenyl-5-benzoxazolyl) propionic acid, m.p. 155° - 157° C.
Analysis : Calculated C : 72.58, H : 5.37, N : 4.97 Found C : 72.39, H : 5.61, N : 5.14
f. 2-(2-o-Methylphenyl-5-benzoxazolyl) propionic acid, m.p. 107° - 110° C.
Analysis : Calculated C : 72.58, H : 5.37, N : 4.97 Found C : 72.54, H : 5.59, N : 4.77
g. 2-(2-p-Methoxyphenyl-5-benzoxazolyl) propionic acid, m.p. 189° - 191° C.
Analysis : Calculated C : 68.67, H : 5.08, N : 4.71 Found C : 68.42, H : 5.36, N : 4.72
h. 2-(2-o-Hydroxy-p-chlorophenyl-5-benzoxazolyl)-propionitrile, m.p. 143° - 145° C. (with prior softening).
Analysis : Calculated C : 64.3, H : 3.7, N : 9.4 Found C : 64.1, H : 3.5, N : 9.5
i. 2-(2-o-Hydroxy-p-chlorophenyl-5-benzoxazolyl)-propionic acid, m.p. 197° - 200° C.
Analysis : Calculated C : 60.5, H : 3.8, N : 4.4 Found C : 60.65, H : 4.06, N : 4.5
j. 2-(2-p-Chlorophenyl-5-benzoxazolyl)propionitrile, m.p. 150° - 153° C.
Analysis : Calculated C : 67.96, H : 3.92, N : 9.90 Found C : 67.57, H : 3.96, N : 9.25
k. 2-(2-p-Acetylphenyl-5-benzoxazolyl)propionic acid, m.p. 207° - 209° C.
Analysis : Calculated C : 69.90, H : 4.85, N : 4.53 Found C : 69.72, H : 4.75, N : 4.50
EXAMPLE 3
a. 2-(2-p-Bromophenyl-5-benzoxazolyl propionic acid, one third hydrochloride.
This compound was prepared using the procedure described in Example 1. The product, m.p. 195° - 197° C, contained one third of a molecule of hydrogen chloride.
Analysis : Calculated C : 53.60, H : 3.46, N : 3.90 Found C : 53.25, H : 3.37, N : 3.88
b. 2-(2-p-Bromophenyl-5-benzoxazolyl) propionic acid, sodium salt.
2-(2-p-Bromophenyl-5-benzoxazolyl) propionic acid, one third hydrochloride (4.3 g., 0.012 mole.) was ground in 1N-sodium hydroxide solution (20 ml.). To the suspension was added an equal volume of chloroform. The suspension was stirred, then filtered. Recrystallisation of the solid from aqueous ethanol yielded 2-(2-p-bromophenyl-5-benzoxazolyl) propionic acid, sodium salt, m.p. <316° C.
Analysis : Calculated C : 52.19, H : 3.01, N : 3.8 Found C : 51.99, H : 3.17, N : 4.07
EXAMPLE 4
Ethyl 2-(2-phenyl-5-benzoxazolyl) propionate
2-(2-Phenyl-5-benzoxazolyl) propionic acid (10 g., 0.037 mole.) and toluene p-sulphonic acid (0.5 g.) were dissolved in a mixture of benzene (60 ml.) and absolute ethanol (25 ml.). The solution was refluxed for 12 hours. After cooling the solution was washed twice with 2N-sodium hydroxide solution, then several times with water. After drying (Na2 SO4) it was evaporated under reduced pressure to leave ethyl 2-(2-phenyl-5-benzoxazolyl) propionate (8 g.) as an oil, which solidified on cooling, m.p. 45° - 46° C.
Analysis : Calculated C : 73.20, H : 5.80, N : 4.74 Found C : 72.95, H : 5.51, N : 4.79
In a similar manner, the following compound was prepared:
Ethyl 2-(2-p-chlorophenyl-5-benzoxazolyl)propionate, m.p. 59° - 62° C.
Analysis : Calculated C : 65.54, H : 4.89, N : 4.24 Found C : 65.46, H : 4.85, N : 4.11
EXAMPLE 5
2-(2-Phenyl-5-benzoxazolyl) propyl alcohol
An approximately 1M-solution (15 ml.) of diborane in dry tetrahydrofuran was added during 5 minutes to a stirred suspension of 2-(2-phenyl-5-benzoxazolyl) propionic acid (3 g., 0.011 mole.) in dry tetrahydrofuran (10 ml.) at room temperature. The resulting solution was stired for 3.75 hours at room temperature, then poured onto crushed ice (35 g.) containing concentrated hydrochloric acid (75 ml.). The mixture was extracted with chloroform (x2). The combined chloroform extracts were washed twice with a saturated sodium bicarbonate solution, dried (Na2 SO4), and evaporated under reduced pressure to give hydrated 2-(2-phenyl- 5-benzoxazolyl) propyl alcohol (2.56 g.) as a solid, m.p. 99° - 103° C.
Analysis: Calculated (for C16 H15 NO2.1/4H2 O) C : 74.53, H : 6.05, N : 5.43 Found C: 74.74, H : 5.95, N : 5.41
EXAMPLE 6
2-(2-Amino-5-benzoxazolyl) propionic acid
a. 2-(3-Amino-4-hydroxyphenyl) propionic acid
A suspension of 2-(3-amino-4-hydroxyphenyl) propionitrile (10 g. 0.06 mole) in concentrated hydrochloric acid (100 ml.) was refluxed for 2.25 hours. The resulting solution was cooled and the pH adjusted to 5 by the addition of 2N-sodium hydroxide solution. The precipitated solid was filtered off. Recrystallisation of the solid from methanol yielded 2-(3-amino-4-hydroxyphenyl) propionic acid (6 g.), m.p. 167° - 169° C.
Analysis : Calculated C : 59.65, H : 6.12, N : 7.73 Found C: 59.43 H : 6.13, N : 7.94
b. 2-(2-Amino-5-benzoxazolyl) propionic acid
Cyanogen bromide (1.06 g., 0.1 mole.) was added to a stirred suspension of 2-(3-amino-4-hydroxyphenyl) propionic acid (1.8 g., 0.1 mole.) in water (100 ml.). The suspension was stirred at room temperature for a further 41 hours. The pH of the suspension as adjusted to 4 by the addition of 50% w/v sodium hydroxide solution. The suspension was filtered and the solid was washed (X2) with small volumes of water. Recrystallisation of the solid from 50% aqueous methanol gave 2-(2-amino-5-benzoxazolyl) propionic acid (1.46 g.), m.p. 225° - 229° C.
Analysis : Calculated C : 58.24, H : 4.88, N : 13.58 Found C: 58.50, H : 4.85, N : 13.46
EXAMPLE 7
2-(5-Benzoxazolyl) propionic acid
a. Ethyl 2-(3-amino-4-hydroxyphenyl) propionate
A solution of 2-(3-amino-4-hydroxyphenyl) propionic acid (13.82 g., 0.076 mole.) in absolute ethanol (50 ml.) was saturated with dry hydrogen chloride. The solution was refluxed for 5.5 hours. During the first 1.75 hours of reflux, hydrogen chloride was admitted to the solution. The solution was evaporated under reduced pressure to leave an oil. The oil was dissolved in water (50 ml.) and the pH of the solution adjusted to 8 by the addition of sodium bicarbonate. The solution was extracted with ether (X3). The combined ether extracts were dried (Na2 SO4) and evaporated to leave an oil. Distillation of the oil yielded ethyl 2-(3-amino-4-hydroxyphenyl) pripionate (8.43 g.), b.p. 154°-156° C/0.25 m.m., m.p. 79° - 82° C.
Analysis : Calculated C : 63.13, H : 7.22, N : 6.69 Found C : 62.48, H : 7.24, N : 6.79
b. Ethyl 2-(3-formamido-4-hydroxyphenyl) pripionate
A solution of ethyl 2-(3-amino-4-hydroxyphenyl) propionate (2 g., 0.01 mole.) in 98% formic acid (10 ml.) was refluxed for 1.5 hours. The solution was evaporated under reduced pressure to leave an oil. The oil was stirred in ether (10 ml.). Filtration yielded ethyl 2-(3-formamido-4-hydroxyphenyl) propionate as a white solid (0.8 g.), m.p, 102° - 104° C.
c. Ethyl 2-(5-benzoxazolyl) propionate
Ethyl 2-(3-formamido-4-hydroxyphenyl) propionate (11.39 g., 0.048 mole.) was heated at 250° C ± 5° C in an oil-bath for 20 minutes. After cooling the coil was dissolved in ethyl acetate. The solution was washed with 2N-sodium hydroxide solution (x4), then with water (x2). The solution was dried (Na2 SO4) and evaporated to give ethyl 2-(5-benzoxazolyl) propionate as an oil (6.55 g.).
d. 2-(5-Benzoxazolyl) propionic acid
A suspension of ethyl 2-(5-benzoxazolyl) propionate (5.75 g., 0.026 mole.) in a solution of sodium hydroxide (1.04 g., 0.026 mole.) in water (150 ml.) was stirred at room temperature for 4.4 hours. The resulting turbid solution was clarified by washing with ethyl acetate (x3) before adjusting the pH to 4 by the addition of concentrated hydrochloric acid. The ensuing turbid solution was saturated with sodium chloride, then extracted with ethyl acetate (x3). The combined ethyl acetate extracts were washed once with saturated aqueous sodium chloride solution, dried (Na2 CO4) and evaporated to leave a solid. The solid was stirred in boiling carbon tetrachloride (150 ml.) and the hot suspension was filtered. The filtrate was evaporated to give 2-(5-benzoxazolyl) propionic acid as a solid (1.24 g.), m.p. 126° - 128.5° C.
EXAMPLE 8
2-Phenyl-5-benzoxazolyl acetic acid
A solution of 2-phenyl-5-benzoxazolylacetonitrile (8.9 gm.)--prepared by the method described in Example 1(e) -- in concentrated hydrochloric acid (80 ml.) was heated on a steam bath for 2.5 hours. The solution was then diluted with ice/water and allowed to stand. The solid produced was crystallised from toluene to give white crystals of 2-phenyl-5-benzoxazolyl acetic acid, m.p. 175° C.
Analysis : Calculated (for C15 H11 NO3) C : 71.1, H : 4.4, N : 5.5 Found C : 71.0, H : 4.4, N : 5.6
EXAMPLE 9
2-Phenyl-6-benzoxazolyl acetic acid
a. 6-Methyl-2-phenylbenzoxazole
Benzoyl chloride (79 ml) was slowly added to a stirred suspension of 6-amino-m-cresol (83 gm) in pyridine (600 ml). The temperature was kept below 5° C. The solution was heated under reflux for 2 hr., then was evaporated to dryness to give an oil. This oil was extracted with aqueous 2N sodium hydroxide solution. The aqueous layer was made acid with cooncentrated hydrochloric acid. The solid, N-(2'-hydroxy-4'-methylbenzanilide), m.p. 170° C, was filtered off. This product was heated until no more water was evolved. The resulting liquid was allowed to cool and the solid produced was powdered and taken up in petroleum ether. The solution was treated with carbon and the filtrate evaporated to dryness to yield 6-methyl-2-phenylbenzoxazole, m.p. 93° C.
b. 6-Bromomethyl-2-phenylbenzoxazole
N-Bromosuccinimide (25.9 gm) was added to a cold solution of 6-methyl-2-phenylbenzoxazole (30 gm) in carbon tetrachloride (250 ml). Benzoyl peroxide (500 mg) was added and the mixture was heated under reflux for 3 hr. in the presence of u.v. light. The solid residue was filtered off. The filtrate was evaporated down slightly, treated with carbon and allowed to cool. The crystals which were formed were recrystallised from benzene to yield 6-bromomethyl-2-phenylbenzoxazole, m.p. 162° C.
c. 2-Phenyl-6-benzoxazolylacetonitrile
A mixture of 6-bromomethyl-2-phenylbenzoxazole (40 gm) and sodium cyanide (7.4 gm) in dry dimethylformamide (800 ml) was heated on a steam bath for 3 hr. The mixture was filtered and the filtrate was evaporated to dryness. The solid was recrystallised to give 2-phenyl-6-benzoxazolylacetonitrile as white crystals, m.p. 144° C.
d. 2-Phenyl-6-benzoxazolylacetic acid
A solution of 2-phenyl-6-benzoxazolylacetonitrile (11 gm) in conc. hydrochloric acid (100 ml) was heated on a steam bath for 1 hr. The solution was then allowed to cool. The resultant solid was filtered off and equilibrated between aqueous sodium bicarbonate solution and chloroform. The aqueous sodium layer was made acid with hydrochloric acid and was extracted with chloroform. The chloroform solution was evaporated to dryness. The residue was recrystallised from toluene to give white crystals of 2-phenyl-6-benzoxazolylacetic acid, m.p. 170° C.
Analysis found: C : 71.0, H : 4.4, N : 5.5% C15 H11 NO3 requires: C : 71.1, H : 4.4, N : 5.4%.
EXAMPLE 10
Ethyl 2-phenyl-6-benzoxazolylacetate
A solution of 2-phenyl-6-benzoxazolylacetic acid (20 gm) in ethanol (200 ml) was heated under reflux for 6 hr., during which time dry hydrogen chloride gas was passed through the solution. The residual oil on evaporation of the solution was extracted with ether and this solution as evaporated to dryness. The solid formed was recrystallised from toluene/petroleum ether to yield white crystals of ethyl-2-phenyl-6-benzoxazolylacetate, m.p. 76° C.
Analysis found: C : 72.3, H : 5.4, N : 4.8 C17 H15 NO3 requires: C : 72.6, H : 5.4, N : 5.0.
EXAMPLE 11
Ethyl 2-(2-Phenyl-6-benzoxazoly)propionate
A solution of ethyl 2-phenyl-6-benzoxazolyl acetate (34 gm) in ether (200 ml) was added to a stirred solution of NaNH2 (from 3.2 gm sodium) in liquid ammonia (500 ml). This red mixture was stirred for 15 min., then a solution of methyl iodide (8.5 ml) in ether (10 ml) was added rapidly. When the reaction mixture appeared colourless the reaction was stopped by the addition of excess ammonium chloride. The mixture was evaporated to dryness and the residue was extracted with ether. The ethereal solution was evaporated to dryness to yield white crystals of ethyl 2-(2-phenyl-6-benzoxazolyl)propionate, m.p. 46° C.
Analysis found: C : 73.0, H : 5.7, N : 5.0 C18 H17 NO3 requires: C : 73.2, H : 5.8, N : 4.7.
EXAMPLE 12
2-(2-Phenyl-6-benzoxazolyl) propanol
A solution of lithium aluminium hydride (˜2 gm) in ether (50 ml) was slowly added to a solution of ethyl 2-(2-phenyl-6-benzoxazolyl)-propionate (5 g) in ether (40 ml). The mixture was heated under reflux for 1 hr., then ethyl acetate was slowly added until effervescence ceased. 6-N-Aqueous hydrochloric acid was then added and the ether layer was separated off and dried. Chromatography over silica gel yield pure 2-(2-phenyl-6-benzoxazolyl)-propanol, m.p. 98° C.
Analysis found: C : 76.0, H : 5.8, N : 5.6 C16 H15 NO2 requires: C : 75.9, H : 6.0, N : 5.5.
EXAMPLE 13
2-(2-Phenyl-6-benzoxazolyl) propionamide
A mixture of ethyl 2-(2-phenyl-6-benzoxazolyl) propionate (4.4 g) and ammoniacal glycerol (40 ml) was heated at 150° C in a bomb for 18 hr. The mixture was diluted twofold with water, the resultant white solid filtered off and recrystallized from ethyl acetate to give white crystals of 2-(2-phenyl-6-benzoxazolyl) propionamide, m.p. 193° C.
Analysis found: C : 72.1, H : 5.4, N : 10.7 C16 H14 N2 O2 requires: C : 72.2, H : 5.3, N : 10.5.
By the same method, the following compounds were prepared:
a. 2-(2-Phenyl-5-benzoxazolyl)propionamide, m.p. 202° - 204° C.
Analysis: Calculated C : 72.2, H : 5.3, N : 10.5 Found C : 72.0, H : 5.1, N : 10.4
b. 2-(2-p-Chlorophenyl-5-benzoxazolyl)propionamide, m.p. 245° - 246° C.
Analysis: Calculated C : 63.89, H : 4.35, N : 9.31 Found C : 63.64, H: 4.30, N : 9.22
EXAMPLE 14
2-(2-Phenyl-6-benzoxazolyl) propionic acid
A solution of ethyl 2-(2-phenyl-6-benzoxazolyl) propionate (15 g) in concentrated hydrochloric acid (150 ml) was heated on a steam bath for 6 hr. The solution was cooled and the crystals which formed were filtered off. These were recrystallised from ethanol/water to yield 2-(2-phenyl-6-benzoxazolyl) propionic acid, m.p. 132° C.
Analysis found: C : 71.7, H : 5.0, N : 5.3 C16 H13 NO3 requires: C : 71.9, H : 4.9, N : 5.2%.
EXAMPLE 15
2-(2-p-Chlorophenyl-6-benzoxazolyl) propionic acid
a. 2-(3-Hydroxy-4-amionophenyl) propionic acid hydrochloride
A solution of ethyl 2-(2-phenyl-6-benzoxazolyl) propionate (10 g) in concentrated hydrochloric acid (150 ml) was heated at 160° C for 24 hr. The resulting mixture was evaporated to dryness and the residue was taken up in water. This solution was washed with chloroform then was evaporated to dryness to yield 2-(3-hydroxy-4-aminophenyl) propionic acid hydrochloride as a white powder, m.p. 170° C (dec.).
b. Ethyl 2-(3-hydroxy-4-aminophenyl) propionate
A solution of 2-(3-hydroxy-4-aminophenyl) propionic acid hydrochloride (5 g) in ethanol (100 ml) was saturated with hydrogen chloride and the resulting solution was heated under reflux for 6 hr. The solution was evaporated to dryness and the residue was taken up in ethanol and this solution was neutralised with sodium hydroxide solution. The residue on evaporation was taken up in chloroform and the solution was washed with water. Evaporation of the chloroform solution yielded ethyl 2-(3-hydroxy-4-aminophenyl) propionate, m.p. 114°-5° C.
Analysis found: C : 63.2, H : 7.2, N : 6.9 C11 H15 NO3 requires: C : 63.1, H : 7.2, N : 6.7.
(c) Ethyl 2-(2-p-chlorophenyl-6-benzoxazolyl) propionate
A solution of ethyl (3-hydroxy-4-amionophenyl) propionate (2.5 g) in pyridine (15 ml) was treated with p-chlorobenzoyl chloride (1.65 ml) at 5° C. After stirring for 2 hr. at room temperature the solution was evaporated to dryness.
The residue was heated at 220° C until no more water was evolved, then was allowed to cool. This yielded ethyl 2-(2-p-chlorophenyl-6-benzoxazolyl) propionate.
d. 2-(2-p-Chlorop enyl-6-benzoxazolyl) propionic acid
A solution of ethyl 2-(2-p-chlorophenyl-6-benzoxazolyl) propionate (4 g) in aqueous sodium hydroxide (30 ml) was heated on a steam bath for one-half hr. On cooling the black solution was washed with chloroform. On acidification of the black solution with hydrochloric acid the mixture was extracted with chloroform. This solution on evaporation yielded 2-(2-p-chlorophenyl-6-benzoxazolyl) propionic acid, m.p. 196° C.
Analysis found: C: 63.9, H: 4.2, N: 4.8, Cl: 12.0 C16 H12 CINO3 requires: C: 63.7, H: 4.0, N: 4.6, Cl: 11.8.
In a similar manner, the following compounds were prepared:
a. Ethyl 2-[2-(3,4-methylenedioxyphenyl)-5-benzoxazolyl]propionate, m.p. 76° - 79° C.
Analysis: Calculated C: 67.25, H: 5.0, N: 4.1 Found C: 67.1, H: 5.05, N: 4.4
b. 2-[2-(3,4-Methylenedioxyphenyl)-5-benzoxazolyl]propionic acid, m.p. 185° - 188° C.
Analysis: Calculated C: 65.5, H: 4.2, N: 4.5 Found C: 65.4, H: 3.9, N: 4.7
c. 2-[ -p-Chlorophenyl- 3,4-Dichlorophenyl)-5-benzoxazolyl]propionic acid, m.p. 169° - 173° C.
Analysis: Calculated C: 57.1, H: 3.3, N: 4.2 Found C: 56.9, H: 3.4, N: 4.1
d. 2-[2-(2,4-Dichlorophenyl)-5-benzoxazolyl]propionic acid, m.p. 151° - 153° C.
Analysis: Calculated C: 57.1, H: 3.3, N: 4.2 Found C: 57.1, H: 3.3, N: 4.4
e. Ethyl 2-(2-p-methylsulphonylphenyl-5-benzoxazolyl)propionate, m.p. 141° - 142° C.
Analysis: Calculated C: 61.1, H: 5.1, N: 3.75 Found C: 61.2, H: 5.1, N: 3.6
f. 2-[2-(2-Furyl)-5-benzoxazolyl]propionic acid m.p. 160° - 162° C.
Analysis: Calculated C: 65.4, H: 4.3, N: 5.4 Found: C: 65.3, H: 4.4, N: 5.4
g. 2-(2-Cyclohexyl-5-benzoxazolyl)propionic acid, m.p. 115° - 117° C.
Analysis: Calculated C: 70.30, H: 7.00, N: 5.12 Found C: 70.58, H: 6.86, N: 5.35
h. 2-(2-m-Trifluoromethylphenyl-5-benzoxazolyl)-propionic acid, m.p. 144° - 147° C.
Analysis: Calculated C: 60.89, H: 3.60, N: 4.17 Found: C: 61.05, H: 3.87, N: 4.41
i. 2-[2-(2-Thienyl)-5-benzoxazolyl]propionic acid, m.p. 161° - 163° C.
Analysis: Calculated C: 61.52, H: 4.05, N: 5.12 Found C: 61.72, H: 4.19, N: 5.07
j. 2-(2-o-Chlorophenyl-5-benzoxazolyl)propionic acid, m.p. 101° - 103° C.
Analysis: Calculated C: 63.68, H: 4.01, N: 4.64 Found C: 63.80, H: 4.22, N: 4.82
k. 2-(2-p-Trifluoromethylphenyl-5-benzoxazolyl)-propionic acid m.p. 165° - 168° C.
Analysis: Calculated C: 60.89, H: 3.60, N: 4.17 Found C: 60.76, H: 3.88, N: 4.34
l. 2-(2-p-Iodophenyl-5-benzoxazolyl)propionic acid, m.p. 205° - 208° C.
Analysis: Calculated C: 48.87, H: 3.07, I: 32.27, N: 3.56 Found C: 48.91, H: 2.93, I: 32.51, N: 3.26
m. 2-(2-m-Fluorophenyl-5-benzoxazolyl)propionic acid, m.p. 135° - 141° C.
Analysis: Calculated C: 67.36, H: 4.24, N: 4.91 Found C: 67.46, H: 4.37, N: 5.11
n. 2-[2-(3,5-Dichlorophenyl)-5-benzoxazolyl]propionic acid, m.p. 161° - 165° C.
Analysis: Calculated C: 57.16, H: 3.29, N: 4.16 Found C: 57.13, H: 3.51, N: 4.22
o. 2-(2-o-Fluorophenyl-5-benzoxazolyl)propionic acid, m.p. 180° - 183° C.
Analysis: Calculated C: 67.36, H: 4.24, N: 4.91 Found C: 67.16, H: 4.50, N: 4.91
p. 2-(2-p-Fluorophenyl-6-benzoxazolyl)propionic acid, m.p. 147° C.
Analysis: Calculated C: 67.4, H: 4.2, N: 4.9, F: 6.7 Found C: 67.2, H: 4.4, N: 4.9, F: 6.8
q. 2-(2-p-Chlorophenyl-5-benzoxazolyl)propionic acid, m.p. 188° - 191° C.
Analysis: Calculated C: 63.68, H: 4.00, N: 4.64 Found C: 63.50, H: 4.16, N: 4.72
EXAMPLE 16
2-(2-o-Chlorophenyl-6-benzoxazolyl)propionic acid
a. Ethyl 2-(2-o-chlorophenyl-6-benzoxazolyl)propionate
A solution of o-chlorobenzaldehyde (4.3 g.) and ethyl 2-(3-hydroxy-4-aminophenyl)propionate (6 g.) in toluene (100 ml.) was heated, using a Dean and Stark apparatus to collect the water formed. After 30 minutes the solution was evaporated to dryness. The residue was dissolved in acetic acid (100 ml.), lead tetracetate (15 g.) was added and the solution was heated on a steam bath for 1 hour. The solution was poured into ice/water and extracted with ether to give the oil, ethyl 2-(2-o-chlorophenyl-6-benzoxazolyl)propionate, a sample of which gave a satisfactory micro-analysis.
b. 2-(2-o-Chlorophenyl-6-benzoxazolyl)propionic acid
The ethyl 2-(2-o-chlorophenyl-6-benzoxazolyl)propionate from (a) was stirred with sodium hydroxide solution (50 ml.) After 11/2 hours the solution was evaporated to dryness. Acidification and re-crystallisation from ether gave 2-(2-o-chlorophenyl-6-benzoxazolyl)-propionic acid, m.p. 108° - 110° C.
Analysis found: C: 63.5, H: 4.1, N: 4.8, Cl: 12.0 C16 H12 ClNO3 requires: C: 63.7, H; 4.0, N: 4.6, Cl: 11.8
EXAMPLE 17
2-[2-(3-Pyridyl)-5-benzoxazolyl]propionic acid
Sodium (0.115 g.) was dissolved carefully in methanol (45 ml.) and 3-cyanopyridine (5.2 g.) was added. Next day, acetic acid (0.3 g.) was added followed by 2-(3-amino-4-hydroxyphenyl)propionic acid (9.05 g.). The stirred mixture was heated under reflux for 5 hours. The solid dissolved completely during this time. An equal volume of water was added to the hot solution. On cooling, cream crystals separated which were filtered off and re-crystallized from dimethylformamide-ethanol to yield the desired acid, m.p. 197° - 200° C.
Analysis: Calculated C: 67.2, H: 4.5, N: 10.4 Found C: 67.3, H: 4.3, N: 10.3
In the same way, the following compounds were prepared:
a. 2-[2-(4-Pyridyl)-5-benzoxazolyl]propionic acid, m.p. 247° - 50° C.
Analysis: Calculated C: 67.2, H: 4.5, N: 10.4 Found C: 66.9, H: 4.8, N: 10.2
b. 2-[2-(2-Pyridyl)-5-benzoxazolyl]propionic acid, m.p. 177° - 179° C.
Analysis: Calculated C: 67.2, H: 4.5, N: 10.4 Found C: 67.0, H: 4.5, N: 10.2
c. 2-(2-p-Chlorophenyl-5-benzoxazolyl)propionic acid, m.p. 188° C.
Analysis: Calculated C: 63.68, H: 4.00, N: 4.64 Found C: 63.50, H: 4.16, N: 4.72
EXAMPLE 18
N,N-Diethyl 2-(2-phenyl-5-benzoxazolyl)propionamide
2-(2-Phenyl-5-benzoxazolyl)propionic acid (50 g.) and thionyl chloride (20 ml.) were heated together on a steam bath for 20 minutes. The excess of thionyl chloride was removed by evaporation under reduced pressure. The residue was cooled to 0° C. and treated cautiously with an excess of diethylamine. After 1 hour the reaction mixture was equilibrated between water (100 ml.) and ether (100 ml.). The ether layer was washed three times with water (50 ml.), dried (NaSO4), and evaporated. The residue was chromatographed on silica gel and then re-crystallised from a small volume of ethanol to yield the required diethylamide, m.p. 108° - 110° C.
Analysis: Calculated C: 74.5, H: 6.8, N: 8.7 Found C: 74.6, H: 6.6, N: 8.7
EXAMPLE 19
2-(2-Phenyl-5-benzoxazolyl)propionylhydroxamic acid
A solution of sodium (0.16 g.) in absolute ethanol (5 ml.) was added to a solution of hydroxylamine hydrochloride (0.46 g.) in absolute ethanol (12 ml.). The chilled mixture was filtered and a solution of ethyl 2-(2-phenyl-5-benzoxazolyl)propionate (2.0 g.) in ethanol (10 ml.) was added to the filtrate. On standing at room temperature for 3 days, a precipitate formed which was filtered off. The solid was stirred in aqueous acetic acid and filtered off, dried, and re-crystalised from dimethylformamide-ethanol. The resulting white crystals of the desired hydroxamic acid melted at 204° - 205° C.
Analysis: Calculated C: 68.1, H: 5.0, N: 9.9 Found C: 68.1, H: 5.0, N: 9.75
EXAMPLE 20
2-(p-Chlorophenyl)-5-benzoxazolylacetic acid
A suspension of p-chlorobenzimidoethyl ether hydrochloride (16.5 g.) and 3-amino-4-hydroxyphenylacetic acid (12.53g.)in methanol (75 ml.) was refluxed for 2 hours. After standing at room temperature overnight the white solid product was removed by filtration. Re-crystallisation from ethanol gave the required acid, m.p. 241° - 242° C.
Analysis: Calculated C: 62.61, H: 3.50, N: 4.86 Found C: 62.89, H: 3.59, N: 4.92
EXAMPLE 21
2-(2-p-Chlorophenyl-5-benzoxazolyl)propionic acid, sodium salt, monohydrate
Sodium dicarbonate (1.95 g.) was added to a solution of 2-(2-p-chlorophenyl-5-benzoxazolyl)propionic acid (7 g.) in a mixture of methanol (100 ml.), chloroform (50 ml.) and water (60 ml.). The resulting solution was evaporated to leave a white solid. The solid was washed with chloroform (100 ml.), filtered off and dried to yield the desired sodium salt, monohydrate, m.p. 312° - 314° C.
Analysis: Calculated C: 56.23, H: 3.83, N: 4.09 Found C: 56.65, H: 3.50, N: 3.99
EXAMPLE 22
2-(2-Methyl-5-benzoxazolyl)propionic acid
a. Ethyl 2-(3-acetamido-4-hydroxyphenyl)propionate
A solution of ethyl 2-(3-amino-4-hydroxyphenyl)-propionate (10.46 g.) and acetic anhydride (5.6 g.) in dry pyridine (50 ml.) was heated on a steam bath for 1.25 hours. The reaction mixture was poured into water (500 ml.), precipitating an oil. On cooling the oil solidified. The solid was removed by filtration and washed with water. After drying, ethyl 2-(3-acetamido-4-hydroxyphenyl)propionate (8.25 g.) was obtained, m.p. 137° - 141° C.
Analysis: Calculated C: 62.13, H: 6.82, N: 5.57 Found C: 61.96, H: 6.63, N: 5.81
b. Ethyl 2-(2-methyl-5-benzoxazolyl)propionate
This compound was prepared by the method described in Example 7(c) from ethyl 2-(3-acetamido-4-hydroxyphenyl)propionate.
c. 2-(2-Methyl-5-benzoxazolyl)propionic acid
This compound was prepared from ethyl 2-(2-methyl-5-benzoxazolyl)-propionate using the method of Example 7(d), m.p. 115° - 117° C.
Analysis: Calculated C: 64.37, H: 5.40, N: 6.82 Found C: 64.15, H: 5.43, N: 6.85
EXAMPLE 23
2-(2-Phenyl-5-benzoxazolyl)isobutyric acid
By treatment of 2-(2-phenyl-5-benzoxazolyl)propionitrile with methyl iodide in the manner described in Example 12, there was obtained 2-(2-phenyl-5-benzoxazolyl)isobutyronitrile which, on treatment with concentrated hydrochloric acid as described in Example 1(f), yielded 2-(2-phenyl-5-benzoxazolylisobutyric acid, m.p. 92° - 95° C.
Analysis: Calculated C: 77.9, H: 5.3, N: 10.7 Found C: 77.6, H: 5.3, N: 10.45
EXAMPLE 24
2-[2-(3-Nitro-4-chlorophenyl)benzoxazol-5-yl]propionic acid
A solution of 3-nitro-4-chlorobenzaldehyde (0.925 g.) and 2-(3-amino-4-hydroxyphenyl)propionic acid (0.900 g.) in ethanol (25 ml.) was heated under reflux for 3.5 hours. The solution was evaporated to give a solid Schiff's base which was dissolved in hot acetic acid (50 ml.). Lead tetracetate (2.8 g.) was added and the reaction was allowed to cool to room temperature. Next morning, water (200 ml.) was added which resulted in the deposition of a sticky solid. The latter was dried and triturated with a small amount of chloroform to yield the pure benzoxazole acid (0.5 g.), m.p. 210° -213° C.
Analysis: Calculated C: 55.4, H: 3.2, N: 8.1 Found C: 55.2, H: 3.2, N: 8.05
In a similar manner, the following compound was prepared: 2-(2-p-Nitrophenyl-5-benzoxazolyl)propionic acid, m.p. 211° - 217° C.
Analysis: Calculated C: 61.53, H: 3.87, N: 8.97 Found C: 61.29, H: 3.75, N: 8.68
EXAMPLE 25
2-(2-Hydroxy-5-benzoxazolyl)propionic acid
Phosgene was bubbled through a stirred solution of 2-(3-amino-4-hydroxyphenyl)propionic acid (3.14 g.) in water (30 ml.) and concentrated hydrochloric acid (2 ml.) for 2 hours. During this time, a small amount of tar was deposited. The aqueous solution was decanted and kept at room temperature for 3 days. A solid was precipitated which was filtered off and recrystallised from 50% aqueous isopropanol to yield the desired hydroxy compound as crystals, m.p. 174° - 176° C.
Analysis: Calculated C: 57.96, H: 4.37, N: 6.76 Found C: 58.12, H: 4.36, N: 6.66
EXAMPLE 26
2-Phenyl-6-benzoxazolyl ethanol
Ethyl 2-phenyl-6-benzoxazolylacetate, treated with lithium aluminum hydride in the manner described in Example 13, yielded 2-phenyl-6-benzoxazolyl ethanol, m.p. 89° C.
Analysis found: C : 75.5, H : 5.6, N : 5.8 C15 H13 NO2 requires: C : 75.3, H : 5.5, N : 5.9.
EXAMPLE 27
In a manner similar to that of Example 6(a), the following compounds were prepared:
2-(3-Benzamido-4-hydroxyphenyl)propionic acid, m.p. 189° - 192° C.
2-(3-o-Chlorobenzamido-4-hydroxyphenyl)propionic acid, m.p. 150° - 157° C.
2-(3-p-Chlorobenzamido-4-hydroxyphenyl)propionic acid, m.p. 209° - 216° C.
On heating the foregoing compounds, there were obtained respectively:
2-(2-Phenyl-5-benzoxazolyl)propionic acid, m.p. 177° - 178° C.,
2-(2-o-Chlorophenyl-5-benzoxazolyl)propionic acid, m.p. 102° - 103° C.,
2-(2-p-Chlorophenyl-5-benzoxazolyl)propionic acid, m.p. 188° - 190° C.
In the following Examples of pharmaceutical compositions of the present invention, the term "medicament" is used to indicate the compound 2-(2-p-chlorophenyl-5-benzoxazolyl) propionic acid. That compound may of course be replaced by any other active compound of formula I and the amount of medicament may be increased or decreased depending on the degree of activity of the medicament used.
EXAMPLE 28
Tablets each containing 100 mg of medicament are made as follows:
______________________________________                                    
Medicament            100        mg                                       
Potato starch         38         mg                                       
Lactose               25         mg                                       
Ethyl cellulose (as 20% solution in                                       
                      2          mg                                       
industrial alcohol)                                                       
Alginic acid          7          mg                                       
Magnesium stearate    1          mg                                       
Talc                  2          mg                                       
                      Total 175  mg                                       
______________________________________
The medicament, starch and lactose are passed through a No. 44 mesh B.S.S. sieve and mixed thoroughly. The solution of ethyl cellulose is mixed with the resultant powders which are then passed through a No. 12 mesh B.S.S. sieve. The granules produced are dried at 50°-60° C. and then passed through a No. 16 mesh B.S.S. sieve. The alginic acid, magnesium stearate and talc, previously passed through a No. 60 mesh B.S.S. sieve, are added to the granules, mixed and compressed in a tabletting machine to yield tablets each weighing 175 mg.
EXAMPLE 29
Capsules each containing 200 mg of medicament are made as follows:
______________________________________                                    
Medicament            200 mg                                              
Lactose               48 mg                                               
Magnesium stearate    2 mg                                                
______________________________________
The medicament, lactose and magnesium stearate are passed through a No. 44 mesh B.S.S. sieve and filled into hard gelatine capsules in 250 mg quantities.
EXAMPLE 30
Injection solutions each containing 100 mg of medicament per 5 ml solution are made as follows:
______________________________________                                    
Medicament                100 mg                                          
Sodium hydroxide (10% solution)                                           
                          q.s.                                            
Water for injection       to 5 ml                                         
______________________________________
The medicament is suspended in the water and the sodium hydroxide solution added drop by drop with stirring until the medicament is in solution. The pH of the solution is adjusted to between 8.0 and 8.5, the solution is sterilised by filtration through a bacteria-proof filter and filled into previously sterilised glass ampoules which are then hermetically sealed under aseptic conditions.
EXAMPLE 31
Suppositories each containing 250 mg of medicament are made as follows:
______________________________________                                    
Medicament            250 mg                                              
Theobroma Oil         to 2000 mg                                          
______________________________________
The medicament is passed through a No. 60 mesh B.S.S. sieve and suspended in the theobroma oil previously melted using the minimum of heat necessary The mixture is then poured into a suppository mould of nominal 2 g capacity and allowed to cool.

Claims (7)

We claim:
1. Compound of the formula: ##STR6## wherein the group --CR1 R2 R3 is in the 5- or 6-position of the benzoxazole nucleus, wherein R4 is cyclohexyl, furyl, thienyl, pyridyl, phenyl or phenyl substituted in any available position by one or two substituents selected from halogen, nitro, amino, .[.hydroxy,.]. C1-4 alkyl, C1-4 alkoxy, C1-3 alkyl-CO, C1-4 alkyl sulphonyl or substituted in two adjacent positions by methylene- or ethylene-dioxy, R1 and R2 are independently hydrogen, methyl or ethyl and R3 is:
ii. the group --COOR5, where R5 is C1-4 alkyl; or
the group --CO--R6 where R6 is --NHOH or --NR7 R8 where R7 and R8 are hydrogen; or
iii. the group --CH2 OR9 where R9 is hydrogen or C1-4 alkyl; or
iv. the group --COOH or an alkali or alkaline earth metal, aluminum or ammonium salt thereof.
2. Compound according to claim 1, wherein R1 is hydrogen, R2 is methyl, R3 is --COOR5, where R5 is C1-4 alkyl; or --COOH or an alkali or alkaline earth metal, aluminum or ammonium salt thereof, and R4 is phenyl, monohalogenophenyl or dihalogenophenyl.
3. A compound according to claim 1 in which R1 is H, R2 is H or CH3, R3 is COOH or CONH2, the group CR1 R2 R3 is in the 5 position of the benzoxazole nucleus and R4 is pyridyl phenyl or phenyl substituted by one or two groups selected from halogen, methyl, methoxy, acetyl, methylsulphonyl, .Iadd.or .Iaddend.nitro .[.or hydroxy.]..
4. Compound according to claim 1, wherein R1 is hydrogen, R2 is methyl and R4 is phenyl optionally substituted by one or two substituents selected from halogen, methyl, methoxy, .Iadd.or .Iaddend.nitro .[.or hydroxy.]..
5. Compound according to claim 2 wherein said compound is 2-(2-p-chlorophenyl-5- or 6-benzoxazolyl)propionic acid.
6. Compound according to claim 2, wherein said compound is 2-(2-p-fluorophenyl-5- or 6-benzoxazolyl)propionic acid.
7. Compound according to claim 2, wherein said compound is 2-[2-(2,4-dichlorophenyl)-5- or 6-benzoxazolyl]propionic acid.
US05/764,664 1972-05-18 1977-02-01 Benzoxazole derivatives Expired - Lifetime USRE29608E (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
UK23409/72 1972-05-18
GB2340972A GB1435721A (en) 1972-05-18 1972-05-18 Benzoxazole derivatives
US356251A US3912748A (en) 1972-05-18 1973-05-01 Benzoxazole derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US356251A Reissue US3912748A (en) 1972-05-18 1973-05-01 Benzoxazole derivatives

Publications (1)

Publication Number Publication Date
USRE29608E true USRE29608E (en) 1978-04-11

Family

ID=26256496

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/764,664 Expired - Lifetime USRE29608E (en) 1972-05-18 1977-02-01 Benzoxazole derivatives

Country Status (1)

Country Link
US (1) USRE29608E (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355029A (en) 1981-06-01 1982-10-19 Eli Lilly And Company Combination therapy for rheumatoid arthritis
US20040152140A1 (en) * 2002-12-19 2004-08-05 Kelly Jeffery W. Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20050272704A1 (en) * 2004-05-20 2005-12-08 Kelly Jeffery W Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136773A (en) * 1961-11-27 1964-06-09 Ciba Ltd New 2, 5-dibenzoxazolyl-thiophene derivatives
AU407284B2 (en) 1964-11-12 1968-05-12 Cuba Limited Nsw bb-oxazolyl-stilbene compounds and process for them manufacture
FR2037486A5 (en) 1969-03-03 1970-12-31 Ciba Geigy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3136773A (en) * 1961-11-27 1964-06-09 Ciba Ltd New 2, 5-dibenzoxazolyl-thiophene derivatives
AU407284B2 (en) 1964-11-12 1968-05-12 Cuba Limited Nsw bb-oxazolyl-stilbene compounds and process for them manufacture
FR2037486A5 (en) 1969-03-03 1970-12-31 Ciba Geigy

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355029A (en) 1981-06-01 1982-10-19 Eli Lilly And Company Combination therapy for rheumatoid arthritis
US20040152140A1 (en) * 2002-12-19 2004-08-05 Kelly Jeffery W. Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7214696B2 (en) 2002-12-19 2007-05-08 The Scripps Research Institute Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7560488B2 (en) 2002-12-19 2009-07-14 The Scripps Research Institute Methods for treating transthyretin amyloid diseases
US20100120919A1 (en) * 2002-12-19 2010-05-13 Kelly Jeffery W Methods for treating transthyretin amyloid diseases
US8168663B2 (en) 2002-12-19 2012-05-01 The Scripps Research Institute Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
US8653119B2 (en) 2002-12-19 2014-02-18 The Scripps Research Institute Methods for treating transthyretin amyloid diseases
US20050272704A1 (en) * 2004-05-20 2005-12-08 Kelly Jeffery W Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20050282780A1 (en) * 2004-05-20 2005-12-22 Richard Labaudiniere Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US7868033B2 (en) 2004-05-20 2011-01-11 Foldrx Pharmaceuticals, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US9249112B2 (en) 2011-09-16 2016-02-02 Pfizer Inc. Solid forms of a transthyretin dissociation inhibitor

Similar Documents

Publication Publication Date Title
US3912748A (en) Benzoxazole derivatives
US4182774A (en) Method of inhibiting blood platelet aggregation with 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof
JP2624901B2 (en) Novel derivative having naphthalene structure, method for producing the same and pharmaceutical composition containing the same
CA2075876C (en) Arylethylamines derivatives, process for their preparation and pharmaceutical compositions holding same
US3962452A (en) Benzoxazole derivatives as therapeutics
US4025637A (en) 2,5 OR 2,6 Disubstituted benzoxazoles
US4025636A (en) 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
NZ190512A (en) Hydantoin derivatives and pharmaceutical compositions
CS248035B2 (en) Production method of the(4(oxo-4h)1(-benzopyran-8-yl)carboxyle acides
JPS636066B2 (en)
US5110831A (en) Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
US3975531A (en) 4-(5- And 7-)benzoylindolin-2-ones and pharmaceutical uses thereof
US6673816B1 (en) Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
JPS5815941A (en) Ethanol amine derivative, manufacture and medicinal composition
US4222946A (en) Acylamino furan derivatives
USRE29608E (en) Benzoxazole derivatives
US4694018A (en) Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
JPH0717589B2 (en) Novel 1,3-dicarbonyl compound and composition thereof
GB1564455A (en) Indole derivatives and process for preparing the same
US4021440A (en) Cyanomethyl substituted benzoxazoles
US3962441A (en) Benzoxazole derivatives in treating inflammation, pain and fever
JPH02223548A (en) Lipoxygenase-inhibiting compound and method of inhibiting lipoxygenase therewith
CA1038393A (en) 2,5 or 2,6 disubstituted benzoxazoles
JPH0859458A (en) Therapeutic agent for hyperlipemia containing indane derivative
US4100168A (en) 2,5 OR 2,6-Disubstituted benzoxazoles

Legal Events

Date Code Title Description
AS Assignment

Owner name: BURROUGHS CORPORATION

Free format text: MERGER;ASSIGNORS:BURROUGHS CORPORATION A CORP OF MI (MERGED INTO);BURROUGHS DELAWARE INCORPORATEDA DE CORP. (CHANGED TO);REEL/FRAME:004312/0324

Effective date: 19840530